Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox

Hella Gollasch(Helios Hospital Berlin-Buch), Albrecht Kretzschmar(Roche (Switzerland)), Christian Stroszczynski(University Hospital Carl Gustav Carus), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Isrid Sturm(Helios Hospital Berlin-Buch), Bernhard Gebauer(Charité - Universitätsmedizin Berlin), Daniel Pink(Universitätsmedizin Greifswald)
Journal of Clinical Oncology
July 15, 2004
10.1200/jco.2004.22.14_suppl.3695
Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
|Annals of Oncology|2009|534
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
|Journal of Clinical Oncology|2007|281